Zacks Research Predicts Sanofi’s Q3 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNYFree Report) – Investment analysts at Zacks Research raised their Q3 2025 EPS estimates for Sanofi in a report released on Wednesday, January 22nd. Zacks Research analyst K. Shah now expects that the company will earn $1.59 per share for the quarter, up from their prior estimate of $1.58. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Zacks Research also issued estimates for Sanofi’s Q1 2026 earnings at $1.06 EPS, Q2 2026 earnings at $1.05 EPS, Q4 2026 earnings at $1.20 EPS and FY2026 earnings at $4.78 EPS.

Separately, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th.

View Our Latest Research Report on Sanofi

Sanofi Price Performance

NASDAQ:SNY opened at $52.48 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $133.19 billion, a P/E ratio of 26.78, a P/E/G ratio of 1.19 and a beta of 0.57. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The business’s 50-day moving average is $48.70 and its 200 day moving average is $52.19.

Sanofi (NASDAQ:SNYGet Free Report) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.55 earnings per share.

Institutional Investors Weigh In On Sanofi

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Synergy Asset Management LLC purchased a new stake in shares of Sanofi in the fourth quarter worth approximately $25,000. Northwest Investment Counselors LLC bought a new position in Sanofi in the third quarter worth approximately $29,000. Concord Wealth Partners grew its stake in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares in the last quarter. Fortitude Family Office LLC grew its stake in Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares in the last quarter. Finally, Sunbelt Securities Inc. grew its stake in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Company Profile

(Get Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

See Also

Earnings History and Estimates for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.